Neogenix Oncology, Inc. to Commence Phase I Trial for Therapeutic Antibody for Pancreatic and Colorectal Cancer

GREAT NECK, N.Y.--(BUSINESS WIRE)--Neogenix Oncology, Inc. (Neogenix) announced today that researchers at Duke University Medical Center have received approval to move forward with a Phase I trial of the company’s lead therapeutic antibody, NPC-1C, in patients with advanced stage pancreatic or colorectal cancer. Duke joins Johns Hopkins Hospital which is already conducting the Phase I trial of NPC-1C. In addition to Johns Hopkins, North Shore - LIJ has also enrolled patients on this multi-center study.